Holding on to Sirtex

Sirtex Medical's share price has increased 47% this year, and almost 200% since we first upgraded it in Sirtex enters remission on 8 Nov 10 (Speculative buy – $5.90). Sirtex looks very expensive on traditional valuation metrics, but to call it overvalued is risky. On one hand the maker of liver cancer treatments is growing rapidly and its SIRFLOX study could significantly increase its market share (see Sirtex targets growing market from 14 Mar 14 (Hold – $15.56)). On the other hand, expectations for the business are high and there's always the threat of a superior treatment rendering Sirtex's treatments...

Sirtex Medical's share price has increased 47% this year, and almost 200% since we first upgraded it in Sirtex enters remission on 8 Nov 10 (Speculative buy – $5.90). Sirtex looks very expensive on traditional valuation metrics, but to call it overvalued is risky.

{{content.question}}

SMS Code Sent…

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa

Related Articles